Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)
Launched by KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER · May 8, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The SCALOP Trial is a clinical study designed to compare two different treatments for patients receiving small liver transplants from living donors. The study is looking at whether a medication called octreotide or a surgical method known as splenic artery ligation is better at managing blood flow in these small liver grafts. The main goal is to see which treatment can reduce complications and help patients recover more effectively after their transplant surgery.
To participate in this trial, individuals must be between the ages of 18 and 70 and be undergoing a living donor liver transplant that involves a small graft. Participants will be randomly assigned to receive either octreotide through an IV or undergo splenic artery ligation during their procedure. They will be closely monitored for 90 days and up to one year after surgery to track their recovery, any complications, and overall health. This research could help doctors choose safer and more effective treatments for patients who need small liver grafts.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 and \<70 years
- • 2. Male and female genders
- • 3. Undergoing Living Donor Liver Transplant (LDLT)
- • 4. All indications
- • 5. Receiving a small-for-size graft requiring portal flow modulation
- • 6. Informed consent provided.
- Exclusion Criteria:
- • 1. Deceased Donor Liver Transplantation (DDLT)
- • 2. Dual LDLT or dual LDLT/DDLT
- • 3. Pregnancy
- • 4. Known allergy to Octreotide / Somatostatin analogue
About King Faisal Specialist Hospital & Research Center
King Faisal Specialist Hospital & Research Center (KFSH&RC) is a leading medical institution in Saudi Arabia, dedicated to providing advanced healthcare services, conducting pioneering research, and training healthcare professionals. Founded in 1975, KFSH&RC specializes in comprehensive patient care across various disciplines, including oncology, organ transplantation, and genetics. The center is recognized for its commitment to clinical excellence and innovation, actively participating in clinical trials to enhance treatment options and improve patient outcomes. With state-of-the-art facilities and a multidisciplinary team of experts, KFSH&RC plays a pivotal role in advancing medical knowledge and improving healthcare standards in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riyadh, , Saudi Arabia
Patients applied
Trial Officials
Dieter C. Broering, MD, PhD
Principal Investigator
Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Dimitri A. Raptis, MD, MSc, PhD
Principal Investigator
Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Massimo Malago, MD, PhD
Principal Investigator
Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported